Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101234 | 0.90 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25993246 | 0.90 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25124522 | 0.82 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25993243 | 0.82 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL18499691 | 0.81 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19915498 | 0.81 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL26230924 | 0.81 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19372449 | 0.81 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12245290 | 0.81 | SMN1; SMN2 (0.43) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20016646 | 0.80 | RAB9A (0.42) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133902-A1 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133902-A1 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy | CD47, CD274, PDCD1LG2 | MEN1 134/4885KMT2A 971/4885SMN1; SMN2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.